Artwork for podcast BJGP Interviews
Talking GLP-1s: how GPs see their role in obesity management
Episode 21514th October 2025 • BJGP Interviews • The British Journal of General Practice
00:00:00 00:17:01

Share Episode

Shownotes

Today, we’re speaking to Jadine Scragg, a researcher based at the University of Oxford, and Sabrina Keating about their recent paper published here in the BJGP.

Title of paper: GPs’ perspectives on GLP-1RAs for obesity management: a qualitative study in England

Available at: https://doi.org/10.3399/BJGP.2025.0065

General practitioners (GPs) play a central role in managing obesity yet face significant challenges due to limited treatment options and resource constraints. GLP-1RAs are emerging as a promising treatment for obesity but access in primary care is limited. This study provides new insights into GPs’ perspectives on the integration of GLP-1RAs into primary care, highlighting concerns around resource limitations, health equity, and misuse of the medications.

Transcript

This transcript was generated using AI and has not been reviewed for accuracy. Please be aware it may contain errors or omissions.


Speaker A

00:00:01.200 - 00:01:00.730

Hello and welcome to BJGP Interviews. I'm Nada Khan and I'm one of the associate editors of the bjgp. Thanks for taking the time today to listen to this podcast.


Today we're speaking to Judine Scragg, a researcher based at the University Oxford, and Sabrina Keating, a DPHIL student who's also based at the University of Oxford within the Nuffield Department of Primary Care Health Sciences.


We're here to talk about their recent paper, published here in the BJJP, titled GP's Perspectives on GLP1 Receptor Agonists for Obesity Management A Qualitative Study in England. So, hi, Judine and Sabrina, it's great to meet you both for this chat.


I guess the first thing to say is that this work is really topical at the moment, especially given current plans to increase the rollout of GLP1 receptor agonists into the community. But, Judine, I'll come to you first and I wonder if you could just tell us a bit more about what you wanted to do in this research and why.


Speaker B

00:01:01.510 - 00:02:25.330

Yeah, absolutely. So, for a long time, as you've said, the GLP1s have been very topical, both in clinical groups and with patients as well.


So I'm first and foremost, I'm a weight management researcher and I've done work in populations with people living with type 2 diabetes and polycystic ovary syndrome. And within those populations, one of the things they've constantly asked about is about GLP1s, when do I qualify? When do I get it around?


And similarly with the gps GP groups as well, there's been a lot of questions, there's lots of media about, you know, both good and bad about GLPs and outlining different people's thought processes and are they good? Are they bad?


So what we sought to do with this was to sort of more robustly work out what it is GPs actually feel about the perceived integration of the GLP1s into primary care to very kind of firmly focus on GP specifically.


And this ended up coming at a really timely point, as midway through the study, the NICE guidance was brought out on outlining the plans for how tirepatide would be rolled out. So it was a really timely piece to find out exactly what they were thinking and feeling about how this may impact them and their patients.


So that's really what we set out to do.


Speaker A

00:02:26.200 - 00:02:55.660

Great.


And this was a qualitative interview study of 25 GPs across England working across different roles, and they all had different experience in weight management services. But I really Just wanted to come on to what you found here.


And let's start with an area that's quite a common issue right now, and I certainly don't seem to go a day without a patient asking me about whether they can get a weight loss injection. But what did gps think about navigating these patient requests when they. When they get them?


Speaker C

00:02:56.140 - 00:03:56.260

Yeah. So at kind of the moment we were conducting interviews, that was definitely a real source of sort of frustration and difficulty.


There were quite a few patients presenting, asking for GLP1s, the majority of whom were ineligible often, or would only be eligible through kind of this longer, more drawn out process of accessing specialist care, which in many of the regions just did not exist or was going to take kind of years and years. So it was not necessarily an amazing option.


This kind of left the gps we spoke to in quite an uncomfortable position where they kind of had to play the role of gatekeeper, really manage those expectations and potentially kind of have that compromising sort of interaction with their patients. So certainly the gps that we spoke to had some frustrations associated with that.


Speaker A

00:03:56.820 - 00:04:03.620

Yeah, absolutely. And I suppose it's a little bit about how to manage those requests. So did the gps talk about that at all?


Speaker C

00:04:04.100 - 00:04:31.440

Yeah, there were some different strategies that we heard about. I would say the primary one was just around identifying other options that would be available.


That was more difficult in some cases where patients had already exhausted those options and were feeling quite frustrated.


One of the other strategies that we heard about was testing patients for type 2 diabetes to try to identify whether maybe there was another avenue that they could kind of come in through.


Speaker A

00:04:31.840 - 00:04:47.040

And did they talk at all about private prescribing or. We might come on to this a bit later. But did any of the gps talk about suggesting or dealing with patient requests for private prescriptions?


Because I think that's quite a big industry and a growing industry at the moment as well.


Speaker C

00:04:47.360 - 00:05:42.850

Yes, certainly our sample were very much aware of this going on and it had been kind of entering the remit of their practice, specifically kind of asking for prescriptions to be carried over into NHS care, which most of the time the answer was a pretty concrete and clear no on.


So that could also be quite disappointing, particularly for patients who had come in through other international health systems who are then like, oh, I thought I would surely be able to get this on the nhs. And, yeah, a lot of the services didn't have, like, a great answer or kind of protocol to responding to those requests for private prescription.


So there was also kind of the frustration of okay.


This is taking up quite a lot of our time, quite a lot of our effort that could be put towards other things, especially at a time when we're so overstretched.


Speaker A

00:05:43.810 - 00:06:08.040

And I think that leads on to the next thing I wanted to talk about.


And I think that, as you say, one of the big concerns for GPs, especially given the increasing effort to provide GLP1 agonists to a wider community population, is how we're going to fit this in alongside all the other things that we're doing. So what else did the GP say about this and about the different resource limitations in general practice?


Speaker B

00:06:08.760 - 00:06:09.320

Yeah.


Speaker C

00:06:09.400 - 00:07:15.450

So I think many had an awareness that in kind of an ideal world, this made a lot of sense to be carrying out in primary care.


A GP has that kind of connection, ideally to their patients, and is able to see kind of the broader context of where and how they live, who they are as an individual. But within that, there was an awareness that that was going to be exceedingly difficult given the resource limitations of the time.


So a few of the gps we spoke to were essentially just like, we don't know how this is going to happen. This needs to stay in secondary care. It's just not kind of a viable model.


Others were really worried that some of the components that should be integral to GLP1 delivery, like wraparound care, behavioral and psychological support, were certainly not going to be easy to provide within primary care. And there was a real discomfort of this is just simply not how the medications are or should be used.


Speaker A

00:07:16.570 - 00:07:48.870

Yeah, I guess that goes back to How Current Tier 3 weight management services are provided or were provided, perhaps, in the nhs.


And the fact that you're right, there's a bit of a wraparound system around it, and certainly GLP1 agonists would only have typically been prescribed in those services alongside, as you say, all of the different weight management services. So that's quite a hefty burden for a GP or practice to pick up.


Judine, I don't know if you wanted to comment on that, given your background in weight management research as well.


Speaker B

00:07:49.590 - 00:09:14.320

Yeah, I mean, I think, as Sabrina said, there's definitely concerns, but I think as well, there's definitely some very strong themes of these GLP1 drugs coming in as a very helpful tool as well, in a few different ways.


So, for example, I think one of the gps that we spoke to voiced concerns about how sometimes it's quite tricky for people to navigate the best way to support themselves, to lose weight and to navigate that wraparound care, and they perceived that GLP1 is a really helpful tool to help, particularly some people will find it a bit more tricky to navigate.


You know, all the different referral systems that exist within wraparound care, such as try this dietary program, you might be eligible for this program. And they saw that as a helpful tool to do that. Yeah.


Thinking about some of the other patient groups that we've spoken with, so particularly I'm thinking patients here with type 2 diabetes or with polycystic ovary syndrome. They have often told us when they've tried to access care and they ended up managing to get in through Tier 3 services.


And I used the word managing because obviously that is quite tricky to access. And there are, as we know, very long wait lists across huge areas of the country.


They felt like they really had to advocate for themselves to get to those and have not necessarily found it the easiest setting to navigate from a patient perspective.


Speaker A

00:09:14.800 - 00:09:39.260

Another aspect your participants talked about was health equity, and this is certainly an area we've covered elsewhere in BJJP life. I wrote an about this titled how to drug your way out of an obesity crisis.


And we know that there are other environmental and social determinants of obesity that really need to be a focus here. And Sabrina, I'll come back to you. What did the GP say here about that?


Speaker C

00:09:39.579 - 00:10:32.900

Yeah, I would say that was definitely front and center in many of the conversations that we had. We did also kind of actively sample for general practices and general practitioners within kind of more deprived settings.


There certainly a discomfort of, okay, if these medications are becoming our first line treatment for obesity at kind of like an individual level, a political level, a medical level, does this become our sole solution to obesity and, you know, a real awareness of the consequences that that could have when obesity is a much more embedded issue and the kind of social factors that contributed to people being in these situations in the first place were not going to go. And in that case, some of the momentum to actually addressing them may just be sort of smoothed over.


Speaker A

00:10:34.580 - 00:10:37.940

I guess those things don't really have an easy fix, do they really?


Speaker C

00:10:39.540 - 00:10:54.180

Yeah, which is why there was also that counterbalance. Awareness of these things take time. There might not be that political motivation to solve them in the short term. We do need something immediate.


We just can't let that be everything.


Speaker A

00:10:55.470 - 00:11:02.430

Fair enough. And I think finally some GPs were concerned about the misuse of these injections. So can you talk us through that as well?


Speaker C

00:11:02.750 - 00:12:14.870

Yes. Some of that concern about misuse, was it becoming this overriding treatment for everyone?


I think especially with everything going on in media and patient demand, it's easy to have kind of that kickback response of, oh, gosh, everyone wants these, everyone wants to be slimmer. So that was a source of kind of discomfort, especially when social inequality might be taking the backseat.


There was also just awareness that these medications could cause some really uncomfortable dynamics in consultation, be that around requests or prescribing or discontinuation of the medications. So there was kind of a view that in the future there might be problems to do with the appropriateness of prescribing.


And since patients are coming in and applying potentially actually significant pressure for the medications to be prescribed, GPs are in quite a difficult position to say no to that. One of our participants referred to it as being called in as the policeman to kind of keep an eye on patients and be the one making those calls.


Speaker B

00:12:15.350 - 00:13:03.340

I think one thing that cropped up was sort of that concern there, that if they said no, that ultimately patients would seek to obtain these medications through other avenues, be it private use.


And then there was obviously that very real concern about how do GPs within an NHS setting look after patients who are obtaining these medicines through private resources?


I think some of the participants mentioned that sort of factoring into those dynamics where they couldn't provide the patients with what the patients were explicitly asking for, that there's this sort of sense that the patient will, you know, if they are able to financially, they'll. They'll just simply try get it elsewhere.


And I think that was a source of anxiety for some of our participants about how do they best make sure that these patients are being looked after appropriately.


Speaker A

00:13:03.820 - 00:13:27.600

Yeah, and there's certainly no shortage of different quality of clinics that are providing these different injections as well.


And I guess this is sort of happening now and many local ICBs and PCNs are trying to figure out how to roll out GLP1 agonists and who should be eligible. I just wonder, after doing this research, what you would say to them about the GP perspective here, given your research.


Speaker B

00:13:28.240 - 00:16:02.500

One thing that we are very looking forward to is getting the data on how many patients actually end up taking these, particularly in the first phase of the rollout, because it is quite a small group of people in primary care who are in the first phase. So I think that's going to be really interesting to see, actually. How many people are we talking in primary care? How many people choose to do it?


We talk a lot about how patients really want this, but there are definitely groups of patients that don't want this. We know, for example, when we think about diabetes One of the key drivers of often weight loss and remission is to take themselves off medicines.


So this might not be a thing that's of interest to everybody.


So in terms of advice, I think maybe it's not so much advice as in we are going to be learning a lot over the next few years about how patients actually feel about these. Now they're on offer potentially to them.


And in terms of advice to gps, I think a lot of that is just keeping themselves as, I guess, kind of up to date with other things that they can offer patients in the meantime. As Sabrina said, there's always going to be an influx of patients wanting these and they might not be eligible just yet.


So being able to offer patients something in the meantime is probably something that certainly patients have said to us in the past about. The main thing they feel downhearted with is when they feel like they get nothing at all. So, you know, something is better than nothing.


I mean, a lot of ICBs as well, I think are doing a really good job of putting on their social media or their websites kind of about some information. So I've seen quite a lot of different ICPs put together.


Really lovely patient facing documents to advise them that, you know, when these drugs might make their way to the patients and to sort of help their patients advocate the system a little bit. For example, you know, helpful tips and tricks.


If they're already in specialist weight management, they'll probably contact us about it very shortly and try.


I can see that ICPs are already making really, really helpful patient facing documentation, which I think is a really, of course, really useful trick to manage that patient demand. I can see why that, you know, doing that potentially to stop, you know, dozens and dozens and dozens of patients coming to their doors every day.


But I think there's definitely something to be said for kind of reassuring the patients about when they may be eligible, what they can do in the meantime and that, you know, not to worry, you've not been forgotten. We can't give it just yet, but no, it's happening soon.


Speaker A

00:16:04.250 - 00:16:54.390

And as you say, it's very interesting times around this and things are a bit in flux as different ICBs work out the best way to provide these services to the right patients. So as I said before, I think this is really timely research.


So great to chat to you about it, but I think that's a great place to just wrap things up. So I just really wanted to say thank you both for your time here.


Thanks so much and thank you all very much for your time here and for listening to this BJGP podcast.


Sabrina and Judine's original research article can be found on bjgp.org and the show notes and podcast audio can be found@bjgplife.com and I just wanted to say a special thanks to Sabrina who is on the west coast of the US and had to wake up at 5am for this podcast. So thanks again for joining us here today and thanks to you all again. Bye.


Transcripts

Speaker A:

Hello and welcome to BJGP Interviews.

Speaker A:

I'm Nada Khan and I'm one of the associate editors of the bjgp.

Speaker A:

Thanks for taking the time today to listen to this podcast.

Speaker A:

Today we're speaking to Judine Scragg, a researcher based at the University Oxford, and Sabrina Keating, a DPHIL student who's also based at the University of Oxford within the Nuffield Department of Primary Care Health Sciences.

Speaker A:

We're here to talk about their recent paper, published here in the BJJP, titled GP's Perspectives on GLP1 Receptor Agonists for Obesity Management A Qualitative Study in England.

Speaker A:

So, hi, Judine and Sabrina, it's great to meet you both for this chat.

Speaker A:

I guess the first thing to say is that this work is really topical at the moment, especially given current plans to increase the rollout of GLP1 receptor agonists into the community.

Speaker A:

But, Judine, I'll come to you first and I wonder if you could just tell us a bit more about what you wanted to do in this research and why.

Speaker B:

Yeah, absolutely.

Speaker B:

So, for a long time, as you've said, the GLP1s have been very topical, both in clinical groups and with patients as well.

Speaker B:

So I'm first and foremost, I'm a weight management researcher and I've done work in populations with people living with type 2 diabetes and polycystic ovary syndrome.

Speaker B:

And within those populations, one of the things they've constantly asked about is about GLP1s, when do I qualify?

Speaker B:

When do I get it around?

Speaker B:

And similarly with the gps GP groups as well, there's been a lot of questions, there's lots of media about, you know, both good and bad about GLPs and outlining different people's thought processes and are they good?

Speaker B:

Are they bad?

Speaker B:

So what we sought to do with this was to sort of more robustly work out what it is GPs actually feel about the perceived integration of the GLP1s into primary care to very kind of firmly focus on GP specifically.

Speaker B:

And this ended up coming at a really timely point, as midway through the study, the NICE guidance was brought out on outlining the plans for how tirepatide would be rolled out.

Speaker B:

So it was a really timely piece to find out exactly what they were thinking and feeling about how this may impact them and their patients.

Speaker B:

So that's really what we set out to do.

Speaker A:

Great.

Speaker A:

And this was a qualitative interview study of 25 GPs across England working across different roles, and they all had different experience in weight management services.

Speaker A:

But I really Just wanted to come on to what you found here.

Speaker A:

And let's start with an area that's quite a common issue right now, and I certainly don't seem to go a day without a patient asking me about whether they can get a weight loss injection.

Speaker A:

But what did gps think about navigating these patient requests when they.

Speaker A:

When they get them?

Speaker C:

Yeah.

Speaker C:

So at kind of the moment we were conducting interviews, that was definitely a real source of sort of frustration and difficulty.

Speaker C:

There were quite a few patients presenting, asking for GLP1s, the majority of whom were ineligible often, or would only be eligible through kind of this longer, more drawn out process of accessing specialist care, which in many of the regions just did not exist or was going to take kind of years and years.

Speaker C:

So it was not necessarily an amazing option.

Speaker C:

This kind of left the gps we spoke to in quite an uncomfortable position where they kind of had to play the role of gatekeeper, really manage those expectations and potentially kind of have that compromising sort of interaction with their patients.

Speaker C:

So certainly the gps that we spoke to had some frustrations associated with that.

Speaker A:

Yeah, absolutely.

Speaker A:

And I suppose it's a little bit about how to manage those requests.

Speaker A:

So did the gps talk about that at all?

Speaker C:

Yeah, there were some different strategies that we heard about.

Speaker C:

I would say the primary one was just around identifying other options that would be available.

Speaker C:

That was more difficult in some cases where patients had already exhausted those options and were feeling quite frustrated.

Speaker C:

One of the other strategies that we heard about was testing patients for type 2 diabetes to try to identify whether maybe there was another avenue that they could kind of come in through.

Speaker A:

And did they talk at all about private prescribing or.

Speaker A:

We might come on to this a bit later.

Speaker A:

But did any of the gps talk about suggesting or dealing with patient requests for private prescriptions?

Speaker A:

Because I think that's quite a big industry and a growing industry at the moment as well.

Speaker C:

Yes, certainly our sample were very much aware of this going on and it had been kind of entering the remit of their practice, specifically kind of asking for prescriptions to be carried over into NHS care, which most of the time the answer was a pretty concrete and clear no on.

Speaker C:

So that could also be quite disappointing, particularly for patients who had come in through other international health systems who are then like, oh, I thought I would surely be able to get this on the nhs.

Speaker C:

And, yeah, a lot of the services didn't have, like, a great answer or kind of protocol to responding to those requests for private prescription.

Speaker C:

So there was also kind of the frustration of okay.

Speaker C:

This is taking up quite a lot of our time, quite a lot of our effort that could be put towards other things, especially at a time when we're so overstretched.

Speaker A:

And I think that leads on to the next thing I wanted to talk about.

Speaker A:

And I think that, as you say, one of the big concerns for GPs, especially given the increasing effort to provide GLP1 agonists to a wider community population, is how we're going to fit this in alongside all the other things that we're doing.

Speaker A:

So what else did the GP say about this and about the different resource limitations in general practice?

Speaker B:

Yeah.

Speaker C:

So I think many had an awareness that in kind of an ideal world, this made a lot of sense to be carrying out in primary care.

Speaker C:

A GP has that kind of connection, ideally to their patients, and is able to see kind of the broader context of where and how they live, who they are as an individual.

Speaker C:

But within that, there was an awareness that that was going to be exceedingly difficult given the resource limitations of the time.

Speaker C:

So a few of the gps we spoke to were essentially just like, we don't know how this is going to happen.

Speaker C:

This needs to stay in secondary care.

Speaker C:

It's just not kind of a viable model.

Speaker C:

Others were really worried that some of the components that should be integral to GLP1 delivery, like wraparound care, behavioral and psychological support, were certainly not going to be easy to provide within primary care.

Speaker C:

And there was a real discomfort of this is just simply not how the medications are or should be used.

Speaker A:

Yeah, I guess that goes back to How Current Tier 3 weight management services are provided or were provided, perhaps, in the nhs.

Speaker A:

And the fact that you're right, there's a bit of a wraparound system around it, and certainly GLP1 agonists would only have typically been prescribed in those services alongside, as you say, all of the different weight management services.

Speaker A:

So that's quite a hefty burden for a GP or practice to pick up.

Speaker A:

Judine, I don't know if you wanted to comment on that, given your background in weight management research as well.

Speaker B:

Yeah, I mean, I think, as Sabrina said, there's definitely concerns, but I think as well, there's definitely some very strong themes of these GLP1 drugs coming in as a very helpful tool as well, in a few different ways.

Speaker B:

So, for example, I think one of the gps that we spoke to voiced concerns about how sometimes it's quite tricky for people to navigate the best way to support themselves, to lose weight and to navigate that wraparound care, and they perceived that GLP1 is a really helpful tool to help, particularly some people will find it a bit more tricky to navigate.

Speaker B:

You know, all the different referral systems that exist within wraparound care, such as try this dietary program, you might be eligible for this program.

Speaker B:

And they saw that as a helpful tool to do that.

Speaker B:

Yeah.

Speaker B:

Thinking about some of the other patient groups that we've spoken with, so particularly I'm thinking patients here with type 2 diabetes or with polycystic ovary syndrome.

Speaker B:

They have often told us when they've tried to access care and they ended up managing to get in through Tier 3 services.

Speaker B:

And I used the word managing because obviously that is quite tricky to access.

Speaker B:

And there are, as we know, very long wait lists across huge areas of the country.

Speaker B:

They felt like they really had to advocate for themselves to get to those and have not necessarily found it the easiest setting to navigate from a patient perspective.

Speaker A:

Another aspect your participants talked about was health equity, and this is certainly an area we've covered elsewhere in BJJP life.

Speaker A:

I wrote an about this titled how to drug your way out of an obesity crisis.

Speaker A:

And we know that there are other environmental and social determinants of obesity that really need to be a focus here.

Speaker A:

And Sabrina, I'll come back to you.

Speaker A:

What did the GP say here about that?

Speaker C:

Yeah, I would say that was definitely front and center in many of the conversations that we had.

Speaker C:

We did also kind of actively sample for general practices and general practitioners within kind of more deprived settings.

Speaker C:

There certainly a discomfort of, okay, if these medications are becoming our first line treatment for obesity at kind of like an individual level, a political level, a medical level, does this become our sole solution to obesity and, you know, a real awareness of the consequences that that could have when obesity is a much more embedded issue and the kind of social factors that contributed to people being in these situations in the first place were not going to go.

Speaker C:

And in that case, some of the momentum to actually addressing them may just be sort of smoothed over.

Speaker A:

I guess those things don't really have an easy fix, do they really?

Speaker C:

Yeah, which is why there was also that counterbalance.

Speaker C:

Awareness of these things take time.

Speaker C:

There might not be that political motivation to solve them in the short term.

Speaker C:

We do need something immediate.

Speaker C:

We just can't let that be everything.

Speaker A:

Fair enough.

Speaker A:

And I think finally some GPs were concerned about the misuse of these injections.

Speaker A:

So can you talk us through that as well?

Speaker C:

Yes.

Speaker C:

Some of that concern about misuse, was it becoming this overriding treatment for everyone?

Speaker C:

I think especially with everything going on in media and patient demand, it's easy to have kind of that kickback response of, oh, gosh, everyone wants these, everyone wants to be slimmer.

Speaker C:

So that was a source of kind of discomfort, especially when social inequality might be taking the backseat.

Speaker C:

There was also just awareness that these medications could cause some really uncomfortable dynamics in consultation, be that around requests or prescribing or discontinuation of the medications.

Speaker C:

So there was kind of a view that in the future there might be problems to do with the appropriateness of prescribing.

Speaker C:

And since patients are coming in and applying potentially actually significant pressure for the medications to be prescribed, GPs are in quite a difficult position to say no to that.

Speaker C:

One of our participants referred to it as being called in as the policeman to kind of keep an eye on patients and be the one making those calls.

Speaker B:

I think one thing that cropped up was sort of that concern there, that if they said no, that ultimately patients would seek to obtain these medications through other avenues, be it private use.

Speaker B:

And then there was obviously that very real concern about how do GPs within an NHS setting look after patients who are obtaining these medicines through private resources?

Speaker B:

I think some of the participants mentioned that sort of factoring into those dynamics where they couldn't provide the patients with what the patients were explicitly asking for, that there's this sort of sense that the patient will, you know, if they are able to financially, they'll.

Speaker B:

They'll just simply try get it elsewhere.

Speaker B:

And I think that was a source of anxiety for some of our participants about how do they best make sure that these patients are being looked after appropriately.

Speaker A:

Yeah, and there's certainly no shortage of different quality of clinics that are providing these different injections as well.

Speaker A:

And I guess this is sort of happening now and many local ICBs and PCNs are trying to figure out how to roll out GLP1 agonists and who should be eligible.

Speaker A:

I just wonder, after doing this research, what you would say to them about the GP perspective here, given your research.

Speaker B:

One thing that we are very looking forward to is getting the data on how many patients actually end up taking these, particularly in the first phase of the rollout, because it is quite a small group of people in primary care who are in the first phase.

Speaker B:

So I think that's going to be really interesting to see, actually.

Speaker B:

How many people are we talking in primary care?

Speaker B:

How many people choose to do it?

Speaker B:

We talk a lot about how patients really want this, but there are definitely groups of patients that don't want this.

Speaker B:

We know, for example, when we think about diabetes One of the key drivers of often weight loss and remission is to take themselves off medicines.

Speaker B:

So this might not be a thing that's of interest to everybody.

Speaker B:

So in terms of advice, I think maybe it's not so much advice as in we are going to be learning a lot over the next few years about how patients actually feel about these.

Speaker B:

Now they're on offer potentially to them.

Speaker B:

And in terms of advice to gps, I think a lot of that is just keeping themselves as, I guess, kind of up to date with other things that they can offer patients in the meantime.

Speaker B:

As Sabrina said, there's always going to be an influx of patients wanting these and they might not be eligible just yet.

Speaker B:

So being able to offer patients something in the meantime is probably something that certainly patients have said to us in the past about.

Speaker B:

The main thing they feel downhearted with is when they feel like they get nothing at all.

Speaker B:

So, you know, something is better than nothing.

Speaker B:

I mean, a lot of ICBs as well, I think are doing a really good job of putting on their social media or their websites kind of about some information.

Speaker B:

So I've seen quite a lot of different ICPs put together.

Speaker B:

Really lovely patient facing documents to advise them that, you know, when these drugs might make their way to the patients and to sort of help their patients advocate the system a little bit.

Speaker B:

For example, you know, helpful tips and tricks.

Speaker B:

If they're already in specialist weight management, they'll probably contact us about it very shortly and try.

Speaker B:

I can see that ICPs are already making really, really helpful patient facing documentation, which I think is a really, of course, really useful trick to manage that patient demand.

Speaker B:

I can see why that, you know, doing that potentially to stop, you know, dozens and dozens and dozens of patients coming to their doors every day.

Speaker B:

But I think there's definitely something to be said for kind of reassuring the patients about when they may be eligible, what they can do in the meantime and that, you know, not to worry, you've not been forgotten.

Speaker B:

We can't give it just yet, but no, it's happening soon.

Speaker A:

And as you say, it's very interesting times around this and things are a bit in flux as different ICBs work out the best way to provide these services to the right patients.

Speaker A:

So as I said before, I think this is really timely research.

Speaker A:

So great to chat to you about it, but I think that's a great place to just wrap things up.

Speaker A:

So I just really wanted to say thank you both for your time here.

Speaker A:

Thanks so much and thank you all very much for your time here and for listening to this BJGP podcast.

Speaker A:

Sabrina and Judine's original research article can be found on bjgp.org and the show notes and podcast audio can be found@bjgplife.com and I just wanted to say a special thanks to Sabrina who is on the west coast of the US and had to wake up at 5am for this podcast.

Speaker A:

So thanks again for joining us here today and thanks to you all again.

Speaker A:

Bye.

Chapters

Video

More from YouTube

More Episodes
215. Talking GLP-1s: how GPs see their role in obesity management
00:17:01
214. Receptionists reimagined: How online services are transforming the GP front desk
00:15:38
213. Menopausal symptoms from hormone receptor positive breast cancer treatment
00:24:17
212. Inside the BJGP and editorial insights: Euan Lawson on the future of publishing and how to get published
00:20:45
211. Bridging the gap: GPs, patients, and mental health in perimenopause
00:19:20
210. Balancing safety and access: The GP’s role in isotretinoin management
00:18:11
209. What do patients really want? Rethinking general practice access
00:15:58
208. ADHD medication – practical tips for GPs on how to recognise common side effects and what to do
00:17:46
207. Risk of postural hypotension associated with antidepressants in older adults – what to think about when prescribing
00:14:07
206. The ‘new kid on the block’ – same day versus routine care appointment systems in general practice
00:17:24
205. More chest x-rays lead to earlier lung cancer diagnoses and better cancer survival – what we can be doing differently in practice
00:18:48
204. Using artificial intelligence techniques for early diagnosis of lung cancer in general practice
00:20:10
203. ‘See the symptom, not the pregnancy’- a look at cancer diagnosis during pregnancy
00:14:57
202. Prescribing testosterone in hypoactive sexual desire disorder – how to initiate it, and how to monitor it in general practice
00:18:27
201. Looking back at the BJGP Research Conference 2025
00:13:38
200. The challenges to diagnosing vulval lichen sclerosus and how to get it right
00:18:19
199. Differential attainment in the MRCGP exam – the impact of language of study and what this means for the future of RCGP exams
00:10:50
198. The increasing digitalisation of general practice systems – how it’s impacting patients and what we can do about it
00:16:21
197. Using the PSA test in general practice – how should we approach testing in asymptomatic men?
00:17:42
196. How to approach safety netting in general practice
00:20:42
195. ReSPECT forms in general practice – more than just a DNACPR
00:20:31
194. Providing digital support for cancer survivors – the Renewed trial
00:14:04
193. BJGP’s top 10 most read papers of 2024
00:39:35
192. Standing up for general practice – what it means to be a GP
00:15:45
192. Christmas break, and a return in 2024 with a new podcast!
00:01:09
191. Getting ‘bang for your buck’ for good quality general practice, and why hybrid working leads to fragmented and inefficient care
00:18:32
190. What's it like working in the Deep End Network in Northern Ireland? It's challenging, but ultimately rewarding
00:16:00
189. Looking at how people access (and can’t access) general practice – lessons to take into action
00:18:51
188. Predicting psychosis in general practice - opportunities for earlier diagnosis using PRisk
00:12:16
187. What’s behind decisions to do a diagnostic test in a child in general practice? Lessons from the Netherlands
00:12:42
186. Why current clinical scoring systems don’t work when assessing acutely ill children in general practice
00:15:42
185. The triple whammy effect: Why people from ethnic minorities may not get adequate care for Long Covid
00:15:26
184. Healthcare avoidance during Covid - the increased mortality risk and the reasons why
00:11:42
183. Prescribing beta-blockers for patients with anxiety - GP views on increasing use in practice
00:14:27
182. What predicts unplanned hospital admissions in older adults, and what can we do about it?
00:12:10
181. The first 100 days after childbirth - what do women need in general practice?
00:15:16
180. Early intervention in psychosis and overcoming the lost connection in general practice
00:13:54
179. Taking a trauma-informed care approach in women’s health
00:16:07
BJGP interviews summer break
00:00:36
BJGP interviews summer break
00:00:36
178. How to communicate breast cancer risk in women taking HRT with a family history of breast cancer
00:16:30
177. The problem with defining GP work in terms of sessions – a study of trends in GP working hours and intensity
00:12:09
176. Link workers for social prescribing: the inverse care law and identifying areas of higher need
00:15:13
175. How to work with patients to prevent long-term use of opioids in general practice
00:15:02
174. Risk of Parkinson’s in patients with new onset anxiety – implications for practice
00:11:23
173. Sarcoma: diagnosing this rare type of bone cancer in general practice
00:10:33
172. Anal incontinence after childbirth: how to support women in general practice
00:15:10
171. Consultations patterns in general practice before suicide
00:15:56
170. How patient expectations play a key role in experiences of stopping antidepressants in practice
00:15:09
169. Exploring the 4DSQ as a tool to help patients and clinicians in mental health consultations
00:14:06
168. Celebrating the work of Dr Ben Bowers and Dr Steve Bradley, winners of the 2024 RCGP/SAPC Early Career Researcher Awards
00:18:57
167. A focus on sleep health – and what patients think of psychological interventions for insomnia
00:15:10
166. Referral decisions for younger people with suspected cancer and the system barriers in general practice
00:15:35
165. Perspectives from patients and GPs on how to provide better care for young people with ADHD
00:15:18
164. Asthma deaths in children in the UK: a call to action to prevent deaths in the future
00:16:48
163. How better funding and resources can help Primary Care Networks reduce health inequalities
00:15:58
162. The impact of continuity on mortality in four common and chronic diseases in general practice
00:13:01
161. The challenges and impacts of the Additional Roles Reimbursement Scheme (ARRS) in general practice
00:17:06
160. Improving access to general practice for people with multiple disadvantage
00:15:16
159. BJGP Easter break
00:00:38
158. Addressing child weight issues in the consultation – what could we be doing better in general practice?
00:16:30
157. The shift to online consultations – what is the patient perspective?
00:15:52
156. How can we provide better care for older patients with multiple disadvantage?
00:15:29
155. How can we better manage patients after a hospital admission for asthma?
00:14:00
154. Joining the dots – how do patients and clinicians experience continuity in extended access clinics?
00:15:58
153. What prescription medicines patients share and why
00:11:52
152. Signals before a diagnosis of bipolar disorder and opportunities for earlier diagnosis by GPs
00:15:05
151. BJGP’s top 10 most read papers of 2023
00:32:10
150. Satisfaction with remote consultations and why education matters
00:13:41
149. A paradox of access and how we can address the increasing demand in general practice
00:15:43
148. Providing proactive and holistic palliative care in general practice – exploring the patient perspective
00:12:08
147. Coeliac disease and its diagnosis in primary care – what is the patient experience?
00:14:30
The BJGP Christmas stocking filler podcast
00:45:54
Christmas break
00:01:00
146. Investigating the signals in primary care prescribing before a diagnosis of bladder or renal cancer
00:11:29
145. Strategies for better diagnosis of COPD in primary care – patient coordinators and the GOLD questions
00:13:08
144. How to safely taper off antidepressants – developing resources for patient use
00:14:28
143. What are the trends around private prescribing of opioids in England and why does it matter?
00:13:52
142. Moral distress in family physicians – the impact of societal inequities on doctors
00:14:19
141. Raising awareness of interconception care: what can we be doing to help women between pregnancies?
00:12:44
140. Disparities in Faecal Immunochemical Test (FIT) uptake – ethnicity and deprivation matter
00:14:41
139. Does continuity of care matter? A view from the BJGP and Sir Denis Pereira Gray from the RCGP conference
00:15:46
138. A focus on young people with ulcerative colitis – do they take their treatment and what can GPs do to help?
00:14:20
137. Domestic abuse during the Covid pandemic – patient experiences and how GPs can help
00:15:04
136. Hearing the voice of primary care – what are women’s health needs in practice?
00:15:12
135. Bloods tests in primary care – Why test and what can we learn from looking at current practice?
00:15:53
134. How can we integrate brief conversations about alcohol reduction into practice? Lessons from an Australian intervention
00:16:10
133. A look at how musculoskeletal consultations and prescribing changed during the Covid pandemic
00:11:29
132. Patients and gut feelings, and how to take these into account in the general practice consultation
00:12:48
BJGP podcasts on summer break - and a pitch for the BJGP Research Conference
00:01:33
BJGP podcasts on summer break - and a pitch for the BJGP Research Conference
00:01:33
131. It’s not all about the money – exploring the motivations of Danish GPs
00:15:18
130. Micro-teams in primary care – opportunities and implications for continuity and for patients
00:12:57
129. How to follow-up younger patients with atrial fibrillation and reassess stroke risk in general practice
00:10:29
128. Are there opportunities for earlier diagnosis of non-cancer diseases?
00:15:26
127. Celebrating the work of Dr Sarah Bailey and Dr Ben Brown, winners of the RCGP/SAPC Early Career Researcher Awards
00:14:29
126. Gender differences in pay and uptake of partnership roles – what can we do differently?
00:15:32
125. Results from two national cancer audits – what’s changed in referrals and early diagnosis for cancer between 2014 and 2018?
00:12:56
124. The association between burnout and the increasing prescribing of opioids and antibiotics in practice – what can we do differently?
00:14:05
123. Thinking about the best ways to integrate pharmacists into general practice – views of GPs and pharmacists
00:14:29
122. How the RCGP is supporting research – and how you can get involved
00:10:36
121. Looking at what happens when a GP surgery closes – what are the wider impacts on patients and other practices?
00:14:26
120. Clinical factors and characteristics of men who see their GP before death by suicide
00:11:45
119. Who’s at risk of acute kidney injury? Developing a score to use in general practice amongst patients with hypertension
00:13:34
118. How can GPs better manage breathlessness symptoms and what is the impact of diagnostic delays?
00:14:48
117. How can we improve our care for ethnic minority women through the menopause?
00:14:09
116. The consequences of online access to patient records – what are the views of practice staff?
00:14:30
115. Better colorectal cancer screening - lessons from the CRISP RCT
00:17:20
114. Continuity in the remote age – what is the impact on patients and GPs?
00:17:22
113. Primary care was overlooked in the pandemic - here's how we can do better next time
00:18:19
112. What constitutes good end of life care, and what is the role of general practice?
00:18:10
111. Discussing increasing trends in the diagnosis and treatment of anxiety in Belgium
00:13:54
110. Academic performance in clinical components of the MRCGP – does ethnicity matter?
00:15:36
109. Listening to women’s experiences of heavy menstrual bleeding – what are the implications for GPs?
00:17:55
108. What do GPs think about prescribing aspirin to prevent colorectal cancer in Lynch syndrome?
00:15:39
107. Looking at interventions to reduce antibiotic prescribing in general practice – results from a mixed-methods study
00:19:04
106. Managing patients with acute exacerbations of COPD in primary care – the Australian perspective
00:11:55
105. Home pulse oximetry amongst patients with Covid-19: patient perceptions and GP workload
00:13:13
104. Considering non-drug treatments for people with common mental health issues and socioeconomic disadvantage
00:15:35
103. Adverse drug reactions– how common are these in general practice and what are the implications for practice?
00:16:23
102. Combining vague cancer symptoms to improve referrals for suspected cancer
00:15:38
101. Diagnosing heart failure in primary care – what cut offs should GPs be using for referral based on natriuretic peptide levels?
00:15:22
100. BJGP’s top 10 most read papers of 2022
00:43:37
99. Exploring the reasons why general practice staff are reluctant to register undocumented people
00:18:25
98. Should we prescribe antibiotics to children with uncomplicated chest infections in primary care?
00:14:06
97. Preconception care – what GPs need to know to optimise pregnancy outcomes
00:15:13
96. Examining disparities in continuity of care in some ethnic groups and implications for practice
00:13:33
95. Should we measure blood pressure at night to diagnose hypertension?
00:14:42
94. 'Think gynae’: help seeking behaviour in women with gynaecological cancer
00:14:54
93. Survivorship care for colorectal cancer: pathways for GP led follow up
00:14:37
92. Consequences of patient access to online medical records
00:13:25
91. Common blood tests before cancer diagnosis and implications for primary care
00:14:22
90. Opportunities for earlier diagnosis of psoriasis in general practice
00:14:12
89. Newspapers on the ‘warpath’: portrayal of GPs in the UK media
00:18:18
88. B12 deficiency, patient safety and self-injection
00:14:03
87. Considering symptom appraisal and help seeking for cancer symptoms in older adults
00:17:30
86. When are proton pump inhibitors being inappropriately prescribed?
00:11:22
85. Considering treatment burden in our patients with multimorbidity
00:14:13
84. The golden thread of continuity of care
00:15:13
83. Summer 2022 - a quick update from the editor
00:03:07
82. Perspectives of GPs on diagnosing childhood urinary tract infections
00:12:58
81. Inflammatory marker blood tests suggest a diagnostic window to help earlier Hodgkin lymphoma diagnosis
00:09:59
80. Improving prescribing through feedback at individual patient level
00:15:45
79. Communication of blood test results to patients is often complex and confusing
00:11:59
78. Non-speculum clinician-taken sampling is comparable to self-sampling in cervical screening
00:09:51
77. How significant is abdominal pain when diagnosing intra-abdominal cancers?
00:15:09
76. People with colorectal cancer can show clinical features and abnormal bloods as early as 9-10 months before diagnosis
00:14:01
75. Primary care contacts with children and young people in the first Covid lockdown
00:10:03
74. Type 2 diabetes sub-groups could guide future treatment approaches in primary care
00:13:38
73. Developing a pathway to treat hepatitis C in primary care
00:13:35
72. The NICE traffic light system to assess sick children is not suitable for use as a clinical tool in general practice
00:15:03
71. The GP workforce crisis - how are outcomes associated with different professionals?
00:12:25
70. PRINCIPLE trial findings on the use of colchicine for COVID-19 in the community
00:13:29
69. The rise in prescribing for anxiety in primary care
00:13:30
68. GP wellbeing during the COVID-19 pandemic
00:15:39
67. Austin O'Carroll talks about the Triple F**k Syndrome
00:18:42
66. Do we need greater stratification of routine blood test monitoring in people on DMARDs?
00:13:35
65. Why do GPs rarely do video consultations?
00:17:40
64. Burnout among general practitioners across the world is often at high levels
00:14:22
63. Large prospective cohort study shows no association between breast pain alone and breast cancer
00:13:29
62. Managing emotional distress in people of South Asian origin with long-term conditions
00:15:22
61. Continuity of care for people with dementia is linked to significant clinical benefits
00:12:22
60. The unintended consequences of online consultations
00:10:55
59. Using urine collection devices to reduce urine sample contamination - results from a single-blind randomised controlled trial
00:11:40
58. The use of CXRs varies significantly between practices and addressing this could help with early detection of lung cancer
00:14:56
57. Locum use in England has remained stable in recent years
00:12:26
56. Non-speculum sampling with a clinician boosts cervical screening uptake in older women
00:13:32
55. Iona Heath on rewilding general practice
00:19:01
54. Identifying how GPs spend their time and the everyday obstacles they face
00:19:20
53. How patients feel about GPs using gut feelings
00:13:45
52. Exploring why emergency admission risk prediction software increased admissions in Wales
00:17:48
51. Developing resilience - just another work task for GPs?
00:13:40
50. The challenges of trials to promote physical activity in people with multimorbidity
00:11:57
49. The clinical coding of long Covid is low and variable
00:10:43
48. Continuity of care with a named GP reduces deaths
00:13:44
47. Recommendations for the recognition and management of long Covid
00:16:11
46. Urgent cancer referrals in primary care have more than doubled
00:14:29
45. Social prescribing and link workers in Deep End practices in Glasgow
00:19:13
44. Insights into safety-netting advice in general practice
00:15:24
43. Ondansetron for vomiting in paediatric gastroenteritis
00:10:47
42. Managing lower urinary tract symptoms in primary care
00:14:08
41. The complexity of diagnosing endometriosis in primary care
00:17:05
40. What is the experience of general practice for young people who self-harm?
00:11:39
39. What are the benefits and limitations of a continuous consultation peer-review system?
00:12:40
38. Episode 038: Summer 2021 Update
00:03:50
37. Talking to patients with long-term conditions about benefits and harms of treatment
00:16:28
36. The primary care experience in eight European countries during the first peak of COVID-19
00:14:57
35. Highlights from the July 2021 issue
00:23:57
34. Supporting patients to discontinue benzodiazepines
00:15:43
33. The impact of COVID-19 on migrants and how they access primary care
00:11:45
32. The role of GP outreach settings to help people experiencing homelessness
00:13:17
31. What factors are associated with potentially missed acute deterioration?
00:13:17
30. Remote consultations for people living with dementia and their carers
00:12:20
29. Cervical screening for trans men and non-binary people
00:13:15
28. Highlights from the May 2021 issue
00:31:38
27. Which patients miss appointments in general practice?
00:12:59
26. Targeting hard-to-reach groups to attend for possible cancer symptoms
00:19:30
25. The GP perspective on discontinuing long-term antidepressants
00:15:04
24. Highlights from the April 2021 issue of the BJGP
00:31:36
23. Professor Sir Michael Marmot on Julian Tudor Hart
00:14:14
22. Exploring the role of gut feelings in how GPs diagnose cancer
00:12:36
21. Group consultations in general practice
00:13:41
20. Domestic abuse among female doctors
00:14:19
19. Chronic kidney disease and the high burden of co-morbidity
00:15:06
18. Highlights from the February 2021 issue of the BJGP
00:37:57
17. Getting the right treatment to people in primary care with depression
00:15:57
16. How quickly are people with symptomatic lung cancer getting a pre-diagnostic chest X-ray?
00:10:32
15. Identifying patients at risk of psychosis
00:12:54
14. Remote consulting and the media during COVID-19
00:15:42
13. Approaches to help address missed appointments in general practice
00:13:10
12. High platelet counts and diagnosis in primary care
00:10:40
11. Testing for respiratory tract infection before and after COVID
00:18:02
10. Understanding the management of heart failure with preserved ejection fraction
00:11:13
9. Managing older people's perception of alcohol-related risk
00:12:08
8. End-of-life recognition in primary care in older people
00:13:11
7. Using the National Early Warning Scores (NEWS) in care homes
00:15:04
6. Excess mortality in the first COVID peak
00:11:20
5. Protecting pregnancies from the harmful effects of ACE inhibitors
00:13:47
4. Operational failures in primary care: the real world stresses of being a GP
00:11:41
3. What happens if we don't treat uncomplicated UTIs with antibiotics?
00:10:37
2. Supporting women with female genital mutilation in primary care
00:15:34
1. Impact of COVID-19 on the mental health of older adults
00:11:38